Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86


Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression.

Marino MT, Grilli A, Baricordi C, Manara MC, Ventura S, Pinca RS, Bellenghi M, Calvaruso M, Mattia G, Donati D, Tripodo C, Picci P, Ferrari S, Scotlandi K.

Ann Oncol. 2014 Oct;25(10):2080-6. doi: 10.1093/annonc/mdu249.


miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.

Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, Alberghini M, Grilli A, Knuutila S, Schaefer KL, Mattia G, Negrini M, Picci P, Serra M, Scotlandi K.

J Pathol. 2012 Apr;226(5):796-805. doi: 10.1002/path.3007.


The expression of microRNA-34a is inversely correlated with c-MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients.

Hong JH, Roh KS, Suh SS, Lee S, Sung SW, Park JK, Byun JH, Kang JH.

Tumour Biol. 2015 Dec;36(12):9327-37. doi: 10.1007/s13277-015-3428-9.


Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion.

Karnuth B, Dedy N, Spieker T, Lawlor ER, Gattenlöhner S, Ranft A, Dirksen U, Jürgens H, Bräuninger A.

PLoS One. 2014 Mar 25;9(3):e93067. doi: 10.1371/journal.pone.0093067.


miRNA-34a is associated with docetaxel resistance in human breast cancer cells.

Kastl L, Brown I, Schofield AC.

Breast Cancer Res Treat. 2012 Jan;131(2):445-54. doi: 10.1007/s10549-011-1424-3.


miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.

Corcoran C, Rani S, O'Driscoll L.

Prostate. 2014 Sep;74(13):1320-34. doi: 10.1002/pros.22848.


Expression level of human miR-34a correlates with glioma grade and prognosis.

Gao H, Zhao H, Xiang W.

J Neurooncol. 2013 Jun;113(2):221-8. doi: 10.1007/s11060-013-1119-1.


Cyclin D1 is a useful marker for soft tissue Ewing's sarcoma/peripheral Primitive Neuroectodermal Tumor in children and adolescents: A comparative immunohistochemical study with rhabdomyosarcoma.

Magro G, Brancato F, Musumeci G, Alaggio R, Parenti R, Salvatorelli L.

Acta Histochem. 2015 May-Jun;117(4-5):460-7. doi: 10.1016/j.acthis.2015.01.005.


miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis.

Ogawa T, Saiki Y, Shiga K, Chen N, Fukushige S, Sunamura M, Nagase H, Hashimoto S, Matsuura K, Saijo S, Kobayashi T, Horii A.

Cancer Sci. 2012 Sep;103(9):1737-43. doi: 10.1111/j.1349-7006.2012.02338.x.


Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.

Aaltomaa S, Kärjä V, Lipponen P, Isotalo T, Kankkunen JP, Talja M, Mokka R.

Anticancer Res. 2006 Nov-Dec;26(6C):4873-8.


Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL.

He M, Gao L, Zhang S, Tao L, Wang J, Yang J, Zhu M.

Gastric Cancer. 2014;17(3):431-41. doi: 10.1007/s10120-013-0313-3.


Primary cutaneous and subcutaneous Ewing sarcoma.

Di Giannatale A, Frezza AM, Le Deley MC, Marec-Bérard P, Benson C, Blay JY, Bui B, Judson I, Oberlin O, Whelan J, Gaspar N.

Pediatr Blood Cancer. 2015 Sep;62(9):1555-61. doi: 10.1002/pbc.25535.


EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.

Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL.

Mol Cancer Res. 2012 Aug;10(8):1098-108. doi: 10.1158/1541-7786.MCR-12-0086.


High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.

Marques SC, Ranjbar B, Laursen MB, Falgreen S, Bilgrau AE, Bødker JS, Jørgensen LK, Primo MN, Schmitz A, Ettrup MS, Johnsen HE, Bøgsted M, Mikkelsen JG, Dybkær K.

Exp Hematol. 2016 Apr;44(4):238-46.e2. doi: 10.1016/j.exphem.2015.12.007.


A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis.

Dosaka-Akita H, Hommura F, Mishina T, Ogura S, Shimizu M, Katoh H, Kawakami Y.

Cancer Res. 2001 Mar 15;61(6):2500-4.


Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome.

Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R, De Gaetani C, Capelli G, Cittadini A, Trentini GP.

Int J Cancer. 2002 Feb 10;97(5):671-8.


Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.

Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, Peters GJ, Giaccone G.

PLoS One. 2010 May 14;5(5):e10630. doi: 10.1371/journal.pone.0010630.


Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1.

Hwang SJ, Lee HW, Kim HR, Song HJ, Lee DH, Lee H, Shin CH, Joung JG, Kim DH, Joo KM, Kim HH.

Oncotarget. 2015 Aug 21;6(24):20434-48.


microRNA and Bone Cancer.

Nugent M.

Adv Exp Med Biol. 2015;889:201-30. doi: 10.1007/978-3-319-23730-5_11. Review.


MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer.

Peurala H, Greco D, Heikkinen T, Kaur S, Bartkova J, Jamshidi M, Aittomäki K, Heikkilä P, Bartek J, Blomqvist C, Bützow R, Nevanlinna H.

PLoS One. 2011;6(11):e26122. doi: 10.1371/journal.pone.0026122.

Supplemental Content

Support Center